Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure.
BACKGROUND: Patients with chronic heart failure (HF) are characterized by alterations in matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) levels. However, the impact of hypolipidemic and antioxidant treatment in MMPs and TIMPs is unknown. In the present study, we...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1797093964381159424 |
|---|---|
| author | Tousoulis, D Andreou, I Tentolouris, C Antoniades, C Papageorgiou, N Gounari, P Kotrogiannis, I Miliou, A Charakida, M Trikas, A Stefanadis, C |
| author_facet | Tousoulis, D Andreou, I Tentolouris, C Antoniades, C Papageorgiou, N Gounari, P Kotrogiannis, I Miliou, A Charakida, M Trikas, A Stefanadis, C |
| author_sort | Tousoulis, D |
| collection | OXFORD |
| description | BACKGROUND: Patients with chronic heart failure (HF) are characterized by alterations in matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) levels. However, the impact of hypolipidemic and antioxidant treatment in MMPs and TIMPs is unknown. In the present study, we sought to compare the effects of statins and xanthine oxidase inhibitors on circulating levels of MMPs and TIMPs in patients with chronic HF. METHODS: Forty-two clinically stable patients with mild to moderate HF were randomized to receive rosuvastatin 10 mg or allopurinol 300 mg daily and followed up for 1 month. Serum levels of MMP-2, -9, TIMP-1, and -2 were measured before and after treatment. RESULTS: Levels of MMP-2 and -9 were significantly decreased in the rosuvastatin group (from 251±52 ng/ml and 400±206 ng/ml to 215±47 ng/ml and 309±166 ng/ml, p<0.001 and p<0.05 respectively), but not in the allopurinol group. In the rosuvastatin group, TIMP-2 levels were significantly increased (from 85±17 ng/ml to 93±16 ng/ml, p<0.05), while TIMP-1 remained unchanged. In the allopurinol group, no significant changes were observed regarding the levels of TIMPs. CONCLUSIONS: Short-term rosuvastatin but not allopurinol administration decreases MMP-2 and -9 and increases TIMP-2 levels. |
| first_indexed | 2024-03-07T04:07:35Z |
| format | Journal article |
| id | oxford-uuid:c6b8e2a6-7e25-4d19-94cb-7cfdebe56c47 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:07:35Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:c6b8e2a6-7e25-4d19-94cb-7cfdebe56c472022-03-27T06:40:02ZComparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c6b8e2a6-7e25-4d19-94cb-7cfdebe56c47EnglishSymplectic Elements at Oxford2010Tousoulis, DAndreou, ITentolouris, CAntoniades, CPapageorgiou, NGounari, PKotrogiannis, IMiliou, ACharakida, MTrikas, AStefanadis, C BACKGROUND: Patients with chronic heart failure (HF) are characterized by alterations in matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) levels. However, the impact of hypolipidemic and antioxidant treatment in MMPs and TIMPs is unknown. In the present study, we sought to compare the effects of statins and xanthine oxidase inhibitors on circulating levels of MMPs and TIMPs in patients with chronic HF. METHODS: Forty-two clinically stable patients with mild to moderate HF were randomized to receive rosuvastatin 10 mg or allopurinol 300 mg daily and followed up for 1 month. Serum levels of MMP-2, -9, TIMP-1, and -2 were measured before and after treatment. RESULTS: Levels of MMP-2 and -9 were significantly decreased in the rosuvastatin group (from 251±52 ng/ml and 400±206 ng/ml to 215±47 ng/ml and 309±166 ng/ml, p<0.001 and p<0.05 respectively), but not in the allopurinol group. In the rosuvastatin group, TIMP-2 levels were significantly increased (from 85±17 ng/ml to 93±16 ng/ml, p<0.05), while TIMP-1 remained unchanged. In the allopurinol group, no significant changes were observed regarding the levels of TIMPs. CONCLUSIONS: Short-term rosuvastatin but not allopurinol administration decreases MMP-2 and -9 and increases TIMP-2 levels. |
| spellingShingle | Tousoulis, D Andreou, I Tentolouris, C Antoniades, C Papageorgiou, N Gounari, P Kotrogiannis, I Miliou, A Charakida, M Trikas, A Stefanadis, C Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. |
| title | Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. |
| title_full | Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. |
| title_fullStr | Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. |
| title_full_unstemmed | Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. |
| title_short | Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. |
| title_sort | comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure |
| work_keys_str_mv | AT tousoulisd comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT andreoui comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT tentolourisc comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT antoniadesc comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT papageorgioun comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT gounarip comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT kotrogiannisi comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT milioua comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT charakidam comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT trikasa comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure AT stefanadisc comparativeeffectsofrosuvastatinandallopurinoloncirculatinglevelsofmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesinpatientswithchronicheartfailure |